Maxalt and Initial insomnia - a phase IV clinical study of FDA data

Summary:

Initial insomnia is reported as a side effect among people who take Maxalt (rizatriptan benzoate), especially for people who are female, 50-59 old, also take Xyrem, and have Narcolepsy.

The phase IV clinical study analyzes which people have Initial insomnia when taking Maxalt. It is created by eHealthMe based on reports of 11,566 people who have side effects when taking Maxalt from the FDA, and is updated regularly.

What is Maxalt?

Maxalt has active ingredients of rizatriptan benzoate. It is often used in migraine. eHealthMe is studying from 12,753 Maxalt users. Check the latest studies of Maxalt.

What is Initial insomnia?

Initial insomnia (feeling of inadequate or poor-quality sleep) is found to be associated with 775 drugs and 680 conditions by eHealthMe. Check the latest studies of Initial insomnia.

On Jan, 22, 2026

11,566 people reported to have side effects when taking Maxalt.
Among them, 13 people (0.11%) have Initial insomnia.

Among these 13 people:

What is the gender of people who have Initial insomnia when taking Maxalt? *

female: 84.62 %
male: 15.38 %

What is the age of people who have Initial insomnia when taking Maxalt? *

What are other drugs people take besides Maxalt? *

What are other side effects people have besides Initial insomnia? *

Joint Pain: 4 people, 30.77%
Therapeutic Response Unexpected: 3 people, 23.08%
Fatigue (feeling of tiredness): 3 people, 23.08%
Stress And Anxiety: 3 people, 23.08%
Nausea And Vomiting: 2 people, 15.38%
Pain In Extremity: 2 people, 15.38%
Abdominal Pain Upper: 2 people, 15.38%
Back Pain: 2 people, 15.38%
Bradyphrenia (neurological term referring to the slowness of thought common to many disorders of the brain): 2 people, 15.38%
Chest Pain: 2 people, 15.38%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 38.46%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 30.77%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 15.38%
High Blood Cholesterol: 2 people, 15.38%
Sleep Disorder: 1 person, 7.69%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 7.69%
Pain: 1 person, 7.69%
Libido Decreased (loss of interest in sex): 1 person, 7.69%
Headache (pain in head): 1 person, 7.69%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Maxalt and have Initial insomnia?

- Check whether Initial insomnia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Maxalt:

Maxalt (12,753 reports)

Initial insomnia treatments and more:

Initial insomnia (12,139 reports)

Browse all side effects of Maxalt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Initial insomnia:

Initial insomnia (775 drugs)

Browse all the conditions that are associated with Initial insomnia:

Initial insomnia (680 conditions)

Drugs similar to Maxalt and Initial insomnia :

How the study uses the data?

The study uses data from the FDA. It is based on rizatriptan benzoate (the active ingredients of Maxalt) and Maxalt (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.